NASDAQ:GLUE Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis $6.24 -0.29 (-4.44%) (As of 10:46 AM ET) Add Compare Share Share Today's Range$6.16▼$6.5550-Day Range$3.38▼$6.5352-Week Range$2.44▼$8.84Volume32,310 shsAverage Volume187,190 shsMarket Capitalization$315.19 millionP/E RatioN/ADividend YieldN/APrice Target$13.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Monte Rosa Therapeutics alerts: Email Address Monte Rosa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside110.6% Upside$13.75 Price TargetShort InterestBearish6.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$6,166 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.92) to ($1.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.11 out of 5 starsMedical Sector792nd out of 924 stocksBiological Products, Except Diagnostic Industry126th out of 145 stocks 3.5 Analyst's Opinion Consensus RatingMonte Rosa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMonte Rosa Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Monte Rosa Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.52% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Monte Rosa Therapeutics has recently decreased by 2.80%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMonte Rosa Therapeutics does not currently pay a dividend.Dividend GrowthMonte Rosa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLUE. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Monte Rosa Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for GLUE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Monte Rosa Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Monte Rosa Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,166.00 in company stock.Percentage Held by InsidersOnly 6.50% of the stock of Monte Rosa Therapeutics is held by insiders.Percentage Held by Institutions79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Monte Rosa Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($1.92) to ($1.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monte Rosa Therapeutics is -2.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monte Rosa Therapeutics is -2.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonte Rosa Therapeutics has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Monte Rosa Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMassive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. Click here to get details on this opportunity now. About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Read More GLUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLUE Stock News HeadlinesAugust 20 at 3:00 AM | finanznachrichten.deMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 StudyAugust 19 at 7:00 AM | globenewswire.comMonte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 StudyAugust 22, 2024 | Insiders Exposed (Ad)$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.August 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH), Immunovant (IMVT) and Monte Rosa Therapeutics (GLUE)August 13, 2024 | americanbankingnews.comMonte Rosa Therapeutics (NASDAQ:GLUE) Given New $17.00 Price Target at Wells Fargo & CompanyAugust 9, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)August 8, 2024 | finanznachrichten.deMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 8, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 22, 2024 | Insiders Exposed (Ad)$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.July 8, 2024 | globenewswire.comMonte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation DayJuly 8, 2024 | globenewswire.comMonte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation DayJune 27, 2024 | globenewswire.comMonte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160June 14, 2024 | globenewswire.comMonte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid ArthritisMay 30, 2024 | globenewswire.comMonte Rosa Therapeutics Announces Leadership Team PromotionsMay 30, 2024 | globenewswire.comMonte Rosa Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Aerovate Therapeutics (AVTE)May 21, 2024 | globenewswire.comMonte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel DiseaseMay 18, 2024 | uk.investing.comMonte Rosa Therapeutics sets public offering at $4.70 per shareSee More Headlines Receive GLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today8/22/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLUE CUSIPN/A CIK1826457 Webwww.monterosatx.com Phone617-949-2643FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$13.75 High Stock Price Target$17.00 Low Stock Price Target$11.00 Potential Upside/Downside+120.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,350,000.00 Net MarginsN/A Pretax Margin-12,674.91% Return on Equity-74.13% Return on Assets-49.14% Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.82 Sales & Book Value Annual Sales$5.76 million Price / Sales54.73 Cash FlowN/A Price / Cash FlowN/A Book Value$3.58 per share Price / Book1.74Miscellaneous Outstanding Shares50,512,000Free Float47,229,000Market Cap$315.19 million OptionableOptionable Beta1.39 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Markus Warmuth M.D. (Age 52)President, CEO & Director Comp: $901.35kDr. Owen B. Wallace Ph.D. (Age 55)Chief Scientific Officer Comp: $630.68kDr. Filip Janku M.D. (Age 49)Ph.D., Chief Medical Officer Comp: $658.66kMs. Jennifer ChampouxChief People & Operations OfficerDr. Sharon Townson Ph.D. (Age 49)Chief Technology Officer Dr. John C. Castle Ph.D. (Age 52)Chief Data & Information Officer Mr. Andrew FunderburkSenior VP and Head of IR & Strategic FinanceMr. Philip Nickson J.D. (Age 45)Ph.D., General Counsel Mr. Magnus Walter DPHILSenior Vice President of Drug DiscoveryMr. Edmund Dunn (Age 58)Vice President & Corporate Controller More ExecutivesKey CompetitorsSeres TherapeuticsNASDAQ:MCRBKinnate BiopharmaNASDAQ:KNTEInvivydNASDAQ:IVVDbluebird bioNASDAQ:BLUEC4 TherapeuticsNASDAQ:CCCCView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCBought 132,614 shares on 8/9/2024Ownership: 0.504%Dimensional Fund Advisors LPBought 81,083 shares on 8/9/2024Ownership: 0.304%American Century Companies Inc.Bought 15,562 shares on 8/8/2024Ownership: 0.098%Meeder Asset Management Inc.Bought 10,050 shares on 8/8/2024Ownership: 0.020%Acadian Asset Management LLCBought 43,009 shares on 8/6/2024Ownership: 0.195%View All Insider TransactionsView All Institutional Transactions GLUE Stock Analysis - Frequently Asked Questions How have GLUE shares performed this year? Monte Rosa Therapeutics' stock was trading at $5.65 at the beginning of 2024. Since then, GLUE shares have increased by 15.6% and is now trading at $6.53. View the best growth stocks for 2024 here. How were Monte Rosa Therapeutics' earnings last quarter? Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.07. The business earned $4.70 million during the quarter, compared to the consensus estimate of $3.20 million. When did Monte Rosa Therapeutics IPO? Monte Rosa Therapeutics (GLUE) raised $211 million in an initial public offering on Thursday, June 24th 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share. Who are Monte Rosa Therapeutics' major shareholders? Monte Rosa Therapeutics' top institutional shareholders include Renaissance Technologies LLC (0.50%), Dimensional Fund Advisors LP (0.30%), Bank of New York Mellon Corp (0.22%) and Acadian Asset Management LLC (0.20%). View institutional ownership trends. How do I buy shares of Monte Rosa Therapeutics? Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLUE) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
